Skip to main content

Advances in Alzheimer’s

This activity is supported by an educational grant from Lilly.

Advances in Alzheimer’s

Alzheimer's research and care is changing rapidly. This clinical collection brings together the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

Experts in Conversation

Representation in clinical trials and implementation of blood-based biomarkers

Suzanne Schindler and Charlotte Teunissen highlight discussions at CTAD 2024 on inclusive screening in clinical trials, use of blood-based biomarkers for diagnosis, and patient eligibility and dosing when using anti-amyloid therapies.

Supported by:
  • Lilly
Watch now

Enhancing safety and efficacy in amyloid-targeted therapies

Craig Ritchie and Charlotte Teunissen discuss key research findings from CTAD 2024 on use of donanemab and lecanemab, and approaches to reduce risk of adverse events including ARIA.

Supported by:
  • Lilly
Watch now

Real-world experience with amyloid-targeting therapies and preparedness for fluid biomarkers in practice

Gemma Salvadó, Sharon A Brangman, and Argonde van Harten explore what the latest developments from AAIC 2024 mean for clinical practice. How can blood-based biomarkers best be applied? What should you consider when selecting patients for amyloid-targeting therapies?

Supported by:
  • Lilly
Watch now

Implementing AD biomarkers and amyloid-targeting therapies

Dorota Religa and Robert Perneczky walk us through the most exciting findings from the AD/PD™ and CONy 2024 conferences.

Their discussion focuses on existing and emerging biomarkers and new amyloid-targeting therapies in Alzheimer's disease.

Supported by:
  • Lilly
Watch now

Highlights from CTAD 2024

New indications for anti-amyloid antibody therapies

Juan Fortea comments on future opportunities for anti-amyloid antibody treatment given the consolidation of clinical trial data in the real world.

Supported by:
  • Lilly

Implications of latest data on anti-amyloid antibody therapies

Claire Paquet discusses the implications of the real-world and recommendation data presented on anti-amyloid antibody therapies for Alzheimer’s disease.

Supported by:
  • Lilly

Highlights from AAIC 2024

Potential for blood-based biomarkers

Rik Ossenkoppele discusses the use of blood-based biomarkers for diagnosing Alzheimer’s disease, commenting that they are now able to reliably predict amyloid-positive disease, as well as longitudinal changes, making them a viable alternative to tau PET or neurological exam approaches.

Supported by:
  • Lilly

Is it too soon to use blood-based biomarkers for AD in primary care?

Michelle Mielke comments on the feasibility of using blood-based biomarkers in primary care. With limited research done so far in primary care settings, there remain a number of important practical and clinical questions that need answered. 

Supported by:
  • Lilly

The effects of time on blood-based biomarkers

Petrice Cogswell discusses whether pTau217 and Aβ42/40 can be used to track disease progression or to predict incident amyloid positivity or incident dementia.

Supported by:
  • Lilly

Neurology Update

Covering the latest advances and keeping your practice up to date. Receive newsletters personally curated for the busy neurologist.

Highlights from AD/PD™ and CONy 2024

Research on earlier treatment with anti-amyloid immunotherapies

Oskar Hansson comments on research supporting earlier treatment with anti-amyloid monoclonal antibodies and the importance of amyloid PET imaging for monitoring patients, with the potential to treat less often.

Supported by:
  • Lilly

Latest research on fluid biomarkers

Charlotte Teunissen highlights some of the research presented on AD biomarkers, including a novel assay for multiphosphorylated tau and the impact of confounding factors.

Supported by:
  • Lilly

Sleep disturbance as a risk factor for AD

Lea Grinberg discusses sleep disturbance as a risk factor for Alzheimer’s disease in association with the accumulation of amyloid and tau proteins. 

Supported by:
  • Lilly

Should lecanemab use be extended over 18 months?

Zvezdan Pirtošek comments on the debate he moderated over whether or not lecanemab should be extended beyond 18 months. 

Supported by:
  • Lilly

Keen to learn more from all the key Alzheimer's congresses? (Link opens in a new window)

Explore the full interactive education program, led by world renowned experts in Alzheimer's disease.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register now

This content was originally published on Journey to a New Era for Alzheimer’s Disease, an independent education program developed by Springer Healthcare IME. This program is supported by an educational grant from Lilly. This content is intended for healthcare professionals outside of the UK. 

© 2024 Springer Healthcare Ltd